Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033036 (APC)
 10,214 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Structural alterations in 3q27 affecting the BCL6 locus are among the most frequent changes in B-NHL. The aim of the present study was to establish an interphase-FISH assay for the detection of all diverse BCL6 translocations in B-NHL. Two different approaches were tested, one using a PAC-clone spanning the major breakpoint region (MBR) of BCL6 (span-assay), and another using two BAC clones flanking the MBR (flank-assay). Interphase FISH with the span-assay detected the various BCL6 translocations in seven B-NHL cell lines. The dual-color flank-assay was evaluated in two laboratories independently: in normal controls, the cutoff level for false-positive signals was 2.6%, whereas the cutoff level for false-negatives in the seven cell lines was 7.5%. To test the feasibility of the FISH strategies, 30 samples from patients with B-NHL with cytogenetic abnormalities of 3q27 were evaluated with both assays. In 21 cases, the span-assay indicated a BCL6 rearrangement. In 18 of the 21 cases, the dual-color flank-assay confirmed the translocation including 12 different partner chromosomal loci. The three false-positive cases detected with the span-assay showed trisomy of chromosome 3 by cytogenetic analyses, and they were correctly classified as non-rearranged with the flank-assay. In summary, our FISH strategy using two differently labeled flanking BCL6 BAC probes provides a robust, sensitive, and reproducible method for the detection of common and uncommon abnormalities of BCL6 gene in interphase nuclei. The routine application of this assay to patients with B-NHL will allow the assessment of the diagnostic and prognostic significance of BCL6 rearrangements.
 ...
PMID:Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization. 1151 11

This study aimed to estimate the pretreatment serum levels of SVE-Cadherin, glycosaminoglycams (GAGs) and malondialdehyde (MDA) in order to evaluate their prognostic significance and their role in monitoring tumor response and overall-survival in Non Hodgkin lymphoma (DLCL) patients. Also the work aimed to investigate the relationship between levels of these biochemical markers with LDH level, ESR and tumor stage. For this purpose pretreatment serum levels of these biochemical markers were evaluated in 40 newly diagnosed patients with non-Hodgkin lymphoma (Diffuse large cell type) and studied in relation to expression in healthy control. Our results revealed that serum levels of SVE-Cadherin, GAGs and MDA increased significantly (P<0.05) in NHL patients (DLCL) as compared to control, no significant relation between these parameters and ESR, LDH. However, higher level of SVE-Cadherin was found in stage II, III of the disease as compared to stage IV disease but with no statistical significance. Regarding response to therapy, only MDA showed a significant relation with response of the patient to treatment. Concerning overall survival there is no statistical significance was found between these parameters & OS in NHL patients. Elevated levels of SVE-Cadherin, GAGs and MDA in NHL patients indicate that they may have a role in the pathogenesis of the disease. High level of MDA may be used as a predictor for tumor response to systemic chemotherapy. Low level of SVE-Cadherin in stage IV participates in the invasiveness and metastasis of the disease.
 ...
PMID:Relevance of some serum biomarkers (E cadherin, GAGs & MDA in patients with diffuse large B-cell lymphoma. 1816 16